KBC Group NV Acquires 56,580 Shares of LivaNova PLC (NASDAQ:LIVN)

KBC Group NV boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 130.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,928 shares of the company’s stock after acquiring an additional 56,580 shares during the quarter. KBC Group NV owned 0.18% of LivaNova worth $4,628,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LIVN. Point72 Asset Management L.P. grew its stake in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Point72 DIFC Ltd grew its position in shares of LivaNova by 75,799.6% in the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after buying an additional 181,161 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of LivaNova by 286.4% in the third quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after buying an additional 153,611 shares during the period. Victory Capital Management Inc. increased its stake in shares of LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after buying an additional 133,401 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after acquiring an additional 93,311 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Down 0.2 %

LIVN opened at $50.64 on Friday. The company has a fifty day moving average price of $49.05 and a two-hundred day moving average price of $49.97. LivaNova PLC has a 1-year low of $43.15 and a 1-year high of $64.47. The company has a market cap of $2.75 billion, a P/E ratio of 120.57 and a beta of 1.01. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of recent analyst reports. Robert W. Baird increased their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Buy” and an average target price of $69.17.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.